Shift Towards Targeted Therapies

Novartis' Cosentyx (secukinumab) received approval from the U.S. Food and Drug Administration (FDA) on January 21, 2015, as a biologic for the treatment of moderate-to-severe plaque psoriasis (BLA 125504). Cosentyx is the first monoclonal antibody that selectively inhibits interleukin-17A (IL-17A), a protein that triggers inflammatory responses. This marked a significant turning point in the treatment paradigm for autoimmune diseases, which had previously relied heavily on TNF-alpha inhibitors, shifting it towards interleukin-targeted therapies. It provides patients with an innovative option that precisely targets the cause of the disease, reducing side effects and improving efficacy.

Overwhelming Efficacy in Phase 3 Clinical Trials

The pivotal Phase 3 clinical trials (ERASURE and FIXTURE) demonstrated remarkable efficacy. In the FIXTURE trial, which involved 1,306 participants, the Cosentyx 300mg group achieved a PASI 75 response rate of 77.1% at week 12, demonstrating significant superiority compared to the placebo group (4.9%) and Amgen's Enbrel (etanercept, 44.0%). Furthermore, 59% of patients achieved PASI 90, indicating almost clear skin. These clinical results garnered significant attention from the medical community, offering a new treatment standard for patients with severe psoriasis who were seeking improvement in their skin lesions.

Differentiated Market Positioning

In terms of market positioning, Cosentyx quickly emerged as a strong alternative to existing TNF-alpha inhibitors, such as AbbVie's Humira (adalimumab). The fact that the proportion of patients with 90% or more improvement in their skin was significantly higher than with existing drugs proved to be a key factor in rapidly expanding market share. Subsequently, other IL-17 inhibitors, such as Eli Lilly's Taltz (ixekizumab), were launched, intensifying competition. However, Cosentyx maintained its position as the first approved product. Novartis leveraged its clinical advantages to implement marketing strategies, quickly gaining the trust of healthcare professionals.

Achieved Blockbuster Sales

Commercially, Cosentyx continues to solidify Novartis' position as a leading blockbuster drug. With the global psoriasis biologics market estimated at approximately $14.5 billion by 2025, Cosentyx plays a vital role as a key growth driver for Novartis. In fact, Cosentyx's global sales grew steadily from $6.141 billion in 2024 to $6.668 billion in 2025. This is attributed to the successful expansion of indications to various inflammatory diseases, including psoriatic arthritis and ankylosing spondylitis.

Strategic Reimbursement Negotiations

To ensure market penetration, securing payer coverage for the high launch price was crucial. Novartis negotiated with private and public insurers to encourage formulary listing and implemented patient support programs to reduce out-of-pocket costs and facilitate patient access. The stable accumulation of real-world prescription data through early patient acquisition led to long-term safety validation, creating a virtuous cycle that ensured prescription sustainability. Ultimately, it demonstrates that, in addition to clinical strengths, a multifaceted pricing strategy that includes reimbursement listing and enhanced access to prescriptions is essential for securing long-term market dominance after a new drug's regulatory approval.